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Since the first publication by Henry Krum in 2009 [1], it
has been a bumpy road for renal denervation (RDN) for the
treatment of sympathetic hyperactivity associated disease
states, such as hypertension. After initial positive results
of non-randomised and randomised trials, a true hype arose
with more than 50 companies developing their own RDN
system. The procedure was reimbursed in several countries
in Europe and within a few years 15,000 to 20,000 proce-
dures were performed. However, in 2014, the presentation
of the sham-controlled blinded Symplicity HTN-3 trial at
the scientific sessions of the American College of Cardi-
ology and simultaneous publication in the New England
Journal of Medicine caused a 180° turn in the thinking of
many physicians about this potential novel treatment modal-
ity [2]. In contrast with previous trials, in Symplicity HTN-
3 the mean decrease in office systolic blood pressure was
only 14.13 mmHg in the treated group, but more surpris-
ingly it was 11.74 mmHg in the sham control group. This
resulted in a modest 2.39 mmHg difference in the RDN
treated versus control group, lower than the preset superior-
ity margin of 5 mmHg and thus not statistically significant.
The differences observed using ambulatory blood pressure
measurements (ABPM) were also too small to reach statis-
tical significance (-6.75 mmHg and -4.79 mmHg, respec-
tively; a difference of -1.96 mmHg). The aftermath of these
unexpected results caused subsequent trials to directly sus-
pend patient recruitment. Furthermore, in most countries
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attention for RDN studies and referrals of patients declined
steeply. Several important issues were identified such as the
small number of patients with resistant hypertension being
found to be eligible for RDN [3]. Also, blood pressure re-
sponses to RDN using the commercially available catheters
were found highly variable, with a considerable number of
non-responders. Third, the absence of good predictors and
a periprocedural read-out of response to RDN is seen as
a big caveat. Searching for an explanation for the neutral
results of the Symplicity HTN-3 trial, among others the
efficacy of the used catheter was questioned. In this light,
besides renal nerve ablation with radiofrequency energy us-
ing different catheters, several other techniques came onto
the market using alcohol injection and high frequency ul-
trasound. Also, a system to deliver energy to renal nerves
using low-intensity focused ultrasound through an external
ultrasound source has been developed and is currently being
tested in a first-in-man study.
Alternatively, Prochnau and colleagues used a standard
radiofrequency ablation catheter in their study in the current
issue of the Netherlands Heart Journal [4]. For this study
the authors used 24-hour ABPM instead of the less reli-
able office measurements, both for screening and follow-
up of the patients. A theoretical advantage is the steerabil-
ity of the amount of energy used and in general the great
experience with the described catheter for standard electro-
physiology procedures. Using this catheter it was possible
to induce a larger amount of energy (up to 12 watts in
their hands), potentially inducing deeper penetrating abla-
tions. Unfortunately, the authors do not describe the strat-
egy and/or mean amount of energy used (range 8-12 watts).
Using this technique they were able to reduce ABPM -15/-
7 ± 18/13 mmHg at 12 months of follow-up. Even after
correction for multiple testing this was a statistically sig-
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nificant change compared with the baseline measurements.
However, it must be stated that bias was introduced by ex-
cluding 10 (out of 70) patients who did not respond to the
treatment and were referred for alternative RDN techniques.
Although patients were followed in a stringent way using
ABPM, no firm conclusions can be made on the results of
the current analysis, other than that RDN using this electro-
physiology catheter is safe. The main limitation of the study
is the lack of a control group. We know from contemporary
trials in hypertension that in placebo arms a mean systolic
blood pressure fall of 8.76 mmHg is observed [5]. Taking
this placebo effect into account and including the data of
the non-responders, the results of the current analysis may
well have been neutral.
In general, after an initial phase of testing new treatment
techniques for safety in phase 1-2 trials, the discussed data
stress the need for phase 3 studies in the field of hyperten-
sion, using only a randomised sham-controlled design.
Also, post-hoc analyses from the Symplicity HTN-3 trial
show that patient selection is the key in studying the effi-
cacy of RDN in the treatment of hypertension. These stud-
ies suggest that blood pressure reduction after RDN might
be influenced by the presence of obstructive sleep apnoea
and racial differences and even seems to be time-dependent
[6–8]. Although these analyses are no more than hypothesis
generating, Simplicity HTN-3 has taught us some lessons
for upcoming trial designs.
Future research in renal denervation is likely to focus
on three main areas: improved catheter design/alternative
techniques for effective denervation, periprocedural assess-
ment of the efficacy of denervation, and identification of
the subgroups most likely to benefit from treatment. The
currently running Spyral HTN OFF-MED and Spyral HTN
ON-MED using a multiple electrode catheter will hopefully
shed some light in this era of uncertainty [9]. Otherwise,
going from the bedside back to the bench might be neces-
sary to get this interesting field of research forward.
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